Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: Application of a second-generation encapsulated cell biodelivery device

Alzheimer's Research and Therapy

Volumn 8, Issue 1, 2016, Pages

  Eyjolfsdottir, Helga ^a,b   Eriksdotter, Maria ^a,b   Linderoth, Bengt ^a,b   Lind, Göran ^a,b   Juliusson, Bengt ^c   Kusk, Philip ^c   Almkvist, Ove ^a   Andreasen, Niels ^a,b   Blennow, Kaj ^d   Ferreira, Daniel ^a   Westman, Eric ^a   Nennesmo, Inger ^b   Karami, Azadeh ^a   Darreh Shori, Taher ^a   Kadir, Ahmadul ^a   Nordberg, Agneta ^a,b   Sundström, Erik ^a,e   Wahlund, Lars Olof ^a,b   Wall, Anders ^f   Wiberg, Maria ^a,b   Winblad, Bengt ^a,b   Seiger, Åke ^a,e   Wahlberg, Lars ^a,c   Almqvist, Per ^a,b   more..

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c NsGene Inc   (United States)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Stockholms Sjukhem Foundation   (Sweden)

^f UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; Encapsulated cell biodelivery; Nerve growth factor; Regenerative medicine

Indexed keywords

ACETYLCHOLINESTERASE; AMYLOID BETA PROTEIN[1-42]; CARBON 11; CHOLINE ACETYLTRANSFERASE; CHOLINESTERASE INHIBITOR; NERVE GROWTH FACTOR; NEUROFILAMENT LIGHT CHAIN PROTEIN; NEUROFILAMENT PROTEIN; NICOTINIC RECEPTOR; POLYETHERSULFONE; POLYETHERURETHAN; UNCLASSIFIED DRUG; AMYLOID BETA PROTEIN; AMYLOID BETA-PROTEIN (1-42); MICROCAPSULE; NERVE PROTEIN; NGF PROTEIN, HUMAN; PEPTIDE FRAGMENT; TAU PROTEIN;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN BIOPSY; CASE REPORT; CONSERVATIVE TREATMENT; DELIRIUM; DEVICE REMOVAL; DEVICE SAFETY; DRUG DELIVERY DEVICE; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TOLERABILITY; ENCAPSULATED CELL BIODELIVERY DEVICE; ENZYME ACTIVITY; FATIGUE; FEMALE; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TRANSFER; HEADACHE; HERPES SIMPLEX; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPERTENSION; MALE; MINI MENTAL STATE EXAMINATION; MOLECULARLY TARGETED THERAPY; NAUSEA; NEUROIMAGING; NGF GENE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; PROTEIN EXPRESSION; PROTEIN SECRETION; RHINOPHARYNGITIS; SUBDURAL HEMATOMA; TRANSPOSON; TREATMENT DURATION; VOMITING; BASAL FOREBRAIN; CELL LINE; CEREBROSPINAL FLUID; CLINICAL TRIAL; COGNITION DISORDERS; COHORT ANALYSIS; DIAGNOSTIC IMAGING; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG EFFECTS; METABOLISM; MICROCAPSULE; MIDDLE AGED; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ACETYLCHOLINESTERASE; AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BASAL FOREBRAIN; CAPSULES; CELL LINE; CHOLINE O-ACETYLTRANSFERASE; COGNITION DISORDERS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTOR; NERVE TISSUE PROTEINS; PEPTIDE FRAGMENTS; TAU PROTEINS; TREATMENT OUTCOME;

EID: 84977500348     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-016-0195-9     Document Type: Article

References (46)

1. Prince M, Albanese E, Guerchet M, et al. World Alzheimer report 2014. Dementia and risk reduction: an analysis of protective and modifiable factors. London: Alzheimer's Disease International; September 2014. http://www.alz.co.uk/research/WorldAlzheimerReport2014.pdf. Accessed 27 May 2015.
2. Bartus RT. On neurodegenerative diseases, models, and treatment strategies: lessons learned and lessons forgotten a generation following the cholinergic hypothesis. Exp Neurol. 2000;163:495-529.
3. Fischer W, Wictorin K, Björklund A. Amelioration of cholinergic neuron atrophy and spatial memory impairment in aged rats by nerve growth factor. Nature. 1987;329:65-8.
4. Davis KL, Mohs RC. Enhancement of memory processes in Alzheimer's disease with multiple-dose intravenous physostigmine. Am J Psychiatry. 1982;139:1421-24.
5. Cuello AC, Bruno MA, Allard S, et al. Cholinergic involvement in Alzheimer's disease: a link with NGF maturation and degradation. J Mol Neurosci. 2010;40:230-5.
6. Hefti F, Mash DC. Localization of NGF receptors in the normal human brain and Alzheimer's disease. Neurobiol Aging. 1989;10:75-87.
7. Eriksdotter-Nilsson M, Skirboll S, Ebendal T, et al. NGF treatment promotes development of basal forebrain tissue grafts in the anterior chamber of the eye. Exp Brain Res. 1989;74:89-98.
8. Eriksdotter-Jönhagen M, Nordberg A, Amberla K, et al. Intracerebroventricular infusion of nerve growth factor in three patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 1998;9:246-57.
9. Covaceuszach S, Capsoni S, Ugolini G, et al. Development of a non invasive NGF-based therapy for Alzheimer's disease. Curr Alzheimer Res. 2009;6:158-70.
10. Tuszynski MH, Thal L, Pay M, et al. A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nat Med. 2005;11:551-5.
11. Lee HJ, Lim IJ, Park SW, et al. Human neural stem cells genetically modified to express human nerve growth factor (NGF) gene restore cognition in the mouse with ibotenic acid-induced cognitive dysfunction. Cell Transplant. 2012;21:2487-96.
12. 11C-nicotine binding, blood flow, EEG, and verbal episodic memory in an Alzheimer patient (case report). J Neural Transm Park Dis Dement Sect. 1992;4:79-95.
13. McKelvey L, Shorten GD, O'Keeffe GW. Nerve growth factor-mediated regulation of pain signaling and proposed new intervention strategies in clinical pain management. J Neurochem. 2013;124:276-89.
14. Hao J, Ebendal T, Xu X, et al. Intracerebroventricular infusion of nerve growth factor induces pain-like response in rats. Neurosci Lett. 2000;286:208-12.
15. Sydow O, Hansson P, Young D, et al. Long-term beneficial effects of adrenal medullary autografts supported by nerve growth factor in Parkinson's disease. Eur J Neurol. 1995;5:445-54.
16. Tuszynski MH, U HS, Amaral DG, et al. Nerve growth factor infusion in the primate brain reduces lesion-induced cholinergic neuronal degeneration. J Neurosci. 1990;10:3604-14.
17. Bishop KM, Hofer EK, Mehta A, et al. Therapeutic potential of CERE-110 (AAV2-NGF): targeted, stable, and sustained NGF delivery and trophic activity on rodent basal forebrain cholinergic neurons. Exp Neurol. 2008;211:574-84.
18. Rafii MS, Baumann TL, Bakay RA, et al. A phase 1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimers Dement. 2014;10:571-81.
19. Orive G, Santos E, Poncelet D, et al. Cell encapsulation: technical and clinical advances. Trends Pharmacol Sci. 2015;36:537-46.
20. Eriksdotter-Jönhagen M, Linderoth B, Lind G, et al. Encapsulated cell biodelivery of nerve growth factor to the basal forebrain in patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:18-28.
21. Wahlberg LU, Lind G, Almqvist MP, et al. Targeted delivery of nerve growth factor via encapsulated cell biodelivery in Alzheimer disease: a technology platform for restorative neurosurgery. J Neurosurg. 2012;117:340-7.
22. Ferreira D, Westman E, Eyjolfsdottir H, et al. Brain changes in Alzheimer patients with implanted encapsulated cells releasing nerve growth factor. J Alzheimers Dis. 2015;43:1059-72.
23. Karami A, Eyjolfsdottir H, Vijayaraghavan S, et al. Changes in CSF cholinergic biomarkers in response to cell therapy with NGF in patients with Alzheimer's disease. Alzheimers Dement. 2015;11:1316-28.
24. Fjord-Larsen L, Kusk P, Emerich DF, et al. Increased encapsulated cell biodelivery of nerve growth factor in the brain by transposon-mediated gene transfer. Gene Ther. 2012;19:1010-7.
25. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's disease. Neurology. 1984;34:939-44.
26. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12:189-98.
27. Mátés L, Chuah MI, Belay E, et al. Molecular evolution of a novel hyperactive Sleeping Beauty transposase enables robust stable gene transfer in vertebrates. Nat Genet. 2009;41:753-61.
28. Schaltenbrand G, Wahren W. Atlas for stereotaxy of the human brain: anatomical, physiological and clinical applications. Stuttgart, Germany: George Thieme Verlag; 1977.
29. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's Disease Assessment Scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S13-21.
30. Simmons A, Westman E, Muehlboeck S. The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry. 2011;26:75-82.
31. 11C]nicotine binding assessed by PET: a dual tracer model evaluated in the rhesus monkey brain. Alzheimer Dis Assoc Disord. 1998;12:238-46.
32. 11C-nicotine binding in normal and Alzheimer brains - in vivo assessment using positron emission tomography. Alzheimer Dis Assoc Disord. 1995;9:21-7.
33. 181) in cerebrospinal fluid by the xMAP technology. Clin Chem. 2005;51:336-45.
34. Rosengren LE, Karlsson JE, Karlsson JO. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. J Neurochem. 1996;67:2013-18.
35. Rosengren LE, Wikkelso C, Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Meth. 1994;51:197-204.
36. Darreh-Shori T, Kadir A, Almkvist O, et al. Inhibition of acetylcholinesterase in CSF versus brain assessed by C-PMP PET in AD patients treated with galantamine. Neurobiol Aging. 2008;29:168-84.
37. Vijayaraghavan S, Karami A, Aeinehband H, et al. Regulated extracellular choline acetyltransferase activity - the plausible missing link of the distant action of acetylcholine in the cholinergic anti-inflammatory pathway. PLoS One. 2013;8, e65936.
38. Orellana C, Ferreira D, Muehlboeck JS, et al. Measuring global brain atrophy with the brain volume/cerebrospinal fluid index: normative values, cut-offs and clinical associations. Neurodegener Dis. 2016;16:77-86.
39. Ivics Z, Hackett PB, Plasterk RH, et al. Molecular reconstruction of Sleeping Beauty, a Tc-1 like transposon from fish, and its transposition in human cells. Cell. 1997;91:501-10.
40. Ammar I, Izsvák Z, Ivics Z. The Sleeping Beauty transposon toolbox. Methods Mol Biol. 2012;859:229-40.
41. Ivics Z, Izsvák Z. The expanding universe of transposon technologies for gene and cell engineering. Mob DNA. 2010;1:25.
42. Giller C, Mehta S, Yansak N, et al. Avoidance of electrode related MRI artifact during staged deep brain stimulator implantation. J Neurol Surg A Cent Eur Neurosurg. 2012;73:320-3.
43. Fjord-Larsen L, Kusk P, Tornoe J, et al. Long-term delivery of nerve growth factor by encapsulated cell biodelivery in the Göttingen minipig basal forebrain. Mol Ther. 2010;18:2164-72.
44. Lopez OL, Becker JT, Wisniewski S, et al. Cholinesterase inhibitor treatment alters the natural history of Alzheimer's disease. J Neurol Neurosurg Psychiatry. 2002;72:310-4.
45. Shahim P. Blood biomarkers for traumatic brain injury. Thesis, University of Gothenburg (2015). https://gupea.ub.gu.se/handle/2077/39572. Accessed 18 Jun 2016.
46. Constantinescu R, Holmberg B, Rosengren L, et al. Light subunit of neurofilament triplet protein in the cerebrospinal fluid after subthalamic nucleus stimulation for Parkinson's disease. Acta Neurol Scand. 2011;124:206-10.